Table 1.

Correlations between N-cadherin expression and PCa patients' clinical characteristics.

Clinicopathological parameters	Total (n = 60) (%)	N-cadherin expressiona		P-value S-Tb/M-Wc/χ2d test
		Low (%)	High (%)
Age
Median (IQR)	66 (61-69.75)	66 (59-68.25)	66.5 (62.75-71)	0.191b
Range (Min, Max)	55-76	55-76	57-75
< 65	24 (40.0%)	13 (43.3%)	11 (36.7%)	0.598d
≥ 65	36 (60.0%)	17 (56.7%)	19 (63.3%)
Log2 NDRG1 expressiona
Median (IQR)	-12.4777 (-13.3336--11.6622)	-11.8416 (-12.5765--11.3095)	-13.069 (-13.5803--12.1849)	0.000b*
Range (Min, Max)	-14.2934--10.5782	-14.2934--10.5782	-14.1577--11.507
Low	30 (50.0%)	8 (26.7%)	22 (73.3%)	0.000d
High	30 (50.0%)	22 (73.3%)	8 (26.7%)
Total PSA (t-PSA)
Median (IQR)	17.275 (8.5725-42.4225)	19.76 (8.3675-42.3)	16.285 (8.3325-43.8875)	0.918c
Range (Min, Max)	0.56-85.35	1.05-64.24	0.56-85.35
< 4 ng/ml	5 (8.3%)	3 (10.0%)	2 (6.7%)	0.517d 0.404c
4-10 ng/ml	15 (25.0%)	5 (16.7%)	10 (33.3%)
10-20 ng/ml	13 (21.7%)	7 (23.3%)	6 (20.0%)
> 20 ng/ml	27 (45.0%)	15 (50.0%)	12 (40.0%)
Gleason Score (GS)
< 7	20 (33.3%)	14 (46.7%)	6 (20.0%)	0.074d 0.028c*
7	20 (33.3%)	9 (30.0%)	11 (36.7%)
> 7	20 (33.3%)	7 (23.3%)	13 (43.3%)
Clinical T-stage
T2a	7 (11.7%)	5 (16.7%)	2 (6.7%)	0.282d 0.064c
T2b	14 (23.3%)	9 (30.0%)	5 (16.7%)
T2c	23 (38.3%)	10 (33.3%)	13 (43.3%)
T3a or T3b	16 (26.7%)	6 (20.0%)	10 (33.3%)
Lymph node metastasis
N0	44 (73.3%)	25 (83.3%)	19 (63.3%)	0.080d
N1	16 (26.7%)	5 (16.7%)	11 (36.7%)
Distant metastasis
M0 or Mx	53 (88.3%)	28 (93.3%)	25 (83.3%)	0.421d
M1	7 (11.7%)	2 (6.7%)	5 (16.7%)
TNM stage
I-II	35 (58.3%)	19 (63.3%)	16 (53.3%)	0.432d
III-IV	25 (41.7%)	11 (36.7%)	14 (46.7%)

^* P < 0.05

^a Median mRNA expression of N-cadherin as a cutoff.

^b P-value (2-sided) of Student's t-test.

^c P-value (2-sided) of the Mann-Whitney U test.

^d P-value (2-sided) of Pearson chi-square test or continuity correction for the chi-square test.